Please check your internet connection and try again.
# Sompraz (Somatostatin)
## Overview
Somatostatin is a naturally occurring peptide hormone that inhibits the release of multiple endocrine and gastrointestinal peptides. It has a very short half-life.
## Primary Indications
* **Acute variceal bleeding:** To reduce portal pressure and splanchnic blood flow, thereby decreasing bleeding from esophageal varices.
* **Off-label uses:** Management of certain endocrine tumors, pancreatitis, and other gastrointestinal issues, though efficacy in these may be less established.
## Adult Dosing
* **Acute variceal bleeding:**
* **Bolus:** 1 to 2 mcg/kg administered as a single intravenous bolus.
* **Infusion:** 2.5 to 4 mcg/kg/hour continuous intravenous infusion.
* **Duration:** Typically for 24 to 48 hours, or as clinically indicated.
## Pediatric Dosing
Dosing in pediatric populations is not well-established and should be guided by specialist consultation and available literature. Extrapolation from adult data is not recommended without careful consideration.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment due to the drug's short half-life and rapid metabolism.
## Contraindications
* Known hypersensitivity to somatostatin or its components.
## Adverse Effects
Generally well-tolerated due to short duration of use.
* **Common:** Nausea, vomiting, abdominal cramps, diarrhea, hyperglycemia, hypoglycemia.
* **Less common:** Bradycardia, flushing.
## Key Drug Interactions
Due to its short half-life and mechanism of action, significant drug interactions are unlikely. However, it can affect the absorption of drugs that require gastric acid for absorption.
## Monitoring
* **Glucose levels:** Monitor for hyperglycemia or hypoglycemia.
* **Electrolytes:** Monitor as clinically indicated, especially if gastrointestinal side effects are present.
* **Hemodynamic status:** Monitor vital signs and signs of bleeding.
## Clinical Pearls
* Somatostatin's effect is transient due to its short half-life.
* Octreotide, a longer-acting analog, is often preferred due to its more convenient dosing and prolonged duration of action.
* Ensure the patient has a patent intravenous line for infusion.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing may vary based on specific clinical situations and institutional protocols.
